Adaptimmune Stock Moves Higher On Cancer Deal With Genentech

  • Adaptimmune Therapeutics plc ADAP has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG RHHBY, to develop and commercialize allogeneic cell therapies for oncology indications.
  • The collaboration includes developing allogeneic T-cell therapies for up to five shared cancer targets and personalized allogeneic T-cell therapies.
  • Adaptimmune will be responsible for developing candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to produce T-cells (iT cells). 
  • Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization.
  • Under the terms of the agreement, Adaptimmune will receive an upfront payment of $150 million and additional payments of $150 million over five years.
  • In addition, Adaptimmune may be eligible to receive research, development, regulatory, and commercial milestones payments potentially exceeding $3 billion in aggregate value.
  • Adaptimmune will also receive tiered royalties on net sales in the mid-single to low-double digits. 
  • Adaptimmune has the right to opt-in to a 50/50 U.S. profit/cost share on "off-the-shelf" products. 
  • Price Action: ADAP shares are up 27.1% at $6.28 during the premarket session on the last check Tuesday.

Posted In: Allogeneic Cell TherapyBriefsBiotechLong IdeasNewsPenny StocksHealth CareContractsSmall CapMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.